Last reviewed · How we verify

NCT06550531: HPV-AMP

Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)

Recruiting now Last updated 13 August 2024
What this trial tests

trial in Human Papilloma Virus in 618 participants. Currently enrolling.

Timeline
4 February 2022
Primary endpoint
4 February 2026
4 February 2026

Quick facts

Lead sponsorUniversity Hospital, Brest
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment618
Start date4 February 2022
Primary completion4 February 2026
Estimated completion4 February 2026
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Brest

Who can join

Adults 25 to 38, female only, with Human Papilloma Virus or Infertility, Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Human Papilloma Virus

Currently open trials in the same condition.

Other University Hospital, Brest trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06550531.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing